Streetbeat News

Regulatory

LZM

Lifezone Metals Limited (NYSE:LZM) announced a significant increase in resources at its Kabanga Nickel Project in Tanzania following successful drilling programs and updated mineralization interpretation. The Measured and Indicated Resources increased by 69%, and Inferred Resources by 20%. The company's CEO, Chris Showalter, highlighted the project's potential as a low-cost, long-life producer of nickel, copper, and cobalt, essential for the green energy transition. The Definitive Feasibility Study is expected to be completed by Q3 2024.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 1:47 pm

BCLI

BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) announced a productive meeting with the FDA regarding NurOwn, its ALS treatment. The meeting focused on a Special Protocol Assessment (SPA) for a Phase 3b trial, aiming to secure FDA agreement on trial design elements critical for future marketing approval. BrainStorm will submit documentation for the SPA, and the company's CEO expressed commitment to advancing NurOwn's regulatory path.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 1:41 pm

GDOT

MSFT

PYPL

The fintech industry anticipates significant changes in 2024, with AI integration in financial services, expansion of banking-as-a-service (BaaS), preparation for Payment Services Directive 3 (PSD3), and increased regulatory scrutiny following the collapse of Silicon Valley Bank. Companies to watch include Microsoft in partnership with OpenAI for AI advancements, Green Dot Corporation for BaaS, and Mastercard and PayPal regarding PSD3.

Portfolio Pulse from Neil Dennis

December 07, 2023 | 1:41 pm

BYTS

BYTE Acquisition Corp. (NASDAQ:BYTS) and Airship AI Holdings, Inc. have announced the filing of a definitive proxy statement for their proposed business combination. The Extraordinary General Meeting for BYTE shareholders to vote on the merger is scheduled for December 15, 2023. If approved, the combined entity will be listed on Nasdaq under the ticker symbol 'AISP'. Shareholders as of November 21, 2023, are urged to vote, with BYTE's board recommending approval of the merger.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 1:40 pm

AMD

GLD

GME

GOOG

NVDA

QQQ

SPY

USO

Wall Street futures are trading flat as investors await further monetary policy insights. The S&P 500 Index fell for the third consecutive day, with concerns about overestimating future interest rate cuts. Treasury yields rose slightly, and the Fed's repo facility demand hit a peak, signaling liquidity concerns. The Japanese yen surged after hawkish comments from the Bank of Japan Governor. Crude oil and gold prices saw modest gains. Bitcoin dropped following negative comments from JPMorgan CEO Jamie Dimon. The SPDR S&P 500 ETF Trust (SPY) and Invesco QQQ ETF (QQQ) edged up in premarket trading. Advanced Micro Devices (AMD) rose on news of a shift from NVIDIA (NVDA) to AMD's AI chip by major tech firms. GameStop (GME) fell on revenue miss, Dollar General (DG) rose on earnings beat, and Alphabet (GOOG/GOOGL) increased after unveiling its new AI model.

Portfolio Pulse from Piero Cingari

December 07, 2023 | 1:31 pm

COMS

COMSovereign Holding Corp. (NASDAQ:COMS) filed its annual 10-K report for 2022 and is working to file delinquent quarterly reports for 2023. The company underwent a business transition, including cost-cutting and streamlining its corporate structure, which resulted in a 75% reduction in headcount and consolidation into a single reporting entity. COMSovereign has continued product sales, expanded its partner network, and disposed of non-core assets. The company aims to return to current-filer status and will update shareholders on developments early next year. COMSovereign received a delisting notice from Nasdaq for non-compliance with filing requirements but has been granted a hearing to present its compliance plan.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 1:15 pm

MBOT

Microbot Medical has completed its Good Laboratory Practice (GLP) pivotal pre-clinical study, adhering to FDA-required standards using a porcine model. This marks a significant milestone for the company as it progresses towards potential FDA approval for its medical devices.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 1:13 pm

FRLA

Fortune Rise Acquisition Corp has been granted an extension until January 5, 2024, by a sponsor affiliate to complete its initial business combination, according to an SEC 8K filing.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 1:13 pm

KRRO

Korro Bio, Inc. (KRRO) has nominated KRRO-110, its first RNA editing oligonucleotide candidate from its OPERA platform, for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). KRRO-110 has shown promise in preclinical mouse models, demonstrating the ability to repair the A1AT protein misfolding and reduce liver aggregates. With over 50% editing efficiency and increased secretion of normal A1AT protein, Korro expects to make a regulatory filing in the second half of 2024. AATD is a genetic disorder with limited treatment options, and KRRO-110 could potentially transform the standard of care.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 1:10 pm

DGX

Quest Diagnostics (NYSE:DGX) has been awarded a multi-year contract by the CDC to assess the hepatitis C virus burden in the U.S. This marks a new phase in a decade-long collaboration, where Quest will provide research consulting, laboratory testing, and data analytics services. The project involves HCV antibody and molecular RNA testing on HIPAA-de-identified 'remnant' specimens. The collaboration aims to inform public policy and improve care for individuals with hepatitis C. Quest's extensive experience in hepatitis testing and its large database of de-identified laboratory results will support this initiative.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 1:06 pm